Drug Research
GSKs Lung Cancer ADC Earns FDA Breakthrough Designation
The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year.
The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...
Drug Research
Bayer And NextRNA Partner On New Small Molecule Cancer Drugs
Bayer and NextRNA Therapeutics, a biotechnology company, announced that they would be working together to create a new type of small molecule cancer drug. The two companies agreed to a deal that could be worth over $500 million.
The two...
Drug Research
Strategies To Improve Cell Line Development For Biologics
The capacity of a cell line to create a biologic that is both safe and stable in large numbers may be considerably improved by the use of a variety of procedures by those who develop pharmaceuticals. On the other...
Drug Research
Nuclear Medicine In North America: Market Growth & Trends
The North American nuclear medicine market was estimated to be worth USD 2.05 billion in 2023 and is expected to develop rapidly over the next few years, with a compound annual growth rate (CAGR) of 9.90% through 2029.
Within the...
Drug Research
Bayer & NextRNA Partner In $547Million Cancer Therapy Deal
This summer, Bayer officials made sure Fierce understood that the company's desire for deals hasn't been stifled by a group-wide reorganization. Its most recent partnership aimed at treating cancer indicates that Bayer has, in fact, not lost interest in...
Drug Research
ST Pharm and Quantoom Partner to Enhance RNA Manufacturing Flexibility
ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates the complementary strengths of both companies to enhance the global supply of critical RNA manufacturing...
Drug Research
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
Bridge Biotherapeutics, a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc., a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
